KUALA LUMPUR (Feb 5): The Securities Commission Malaysia (SC) has issued an alert about a potential “clone firm” investment scam that is believed to impersonate Xeraya Capital Sdn Bhd.
The SC said there is a possible clone of Xeraya Capital impersonating the firm as www.xeraya-capital.com, offering high returns for a minimum investment of RM550 within 24 hours.
Xeraya Capital, which is owned by sovereign wealth fund Khazanah Nasional Bhd, acknowledged the SC alert on the firm’s official website at www.xeraya.com.
It however stressed that it is a legitimate business operator with a restricted capital markets services licence.
P2 Science Appoints Daina Catanese as Marketing Specialist
Share Article WOODBRIGE, Conn. (PRWEB) January 22, 2021
P2 Science Inc., a green chemistry company, announced that Daina Catanese has joined the company to lead marketing, communications and media activities.
Catanese has experience in the fields of graphic design and marketing for consumer products companies. She comes to P2 from Kantar Consulting where she provided major multinationals in the health, wellness and beauty space with a range of innovative media content and strategies to support key brands.
“Bringing Daina onto the P2 team is a great opportunity for us to upgrade and accelerate marketing efforts around our unique technology and products for the consumer products industry,” said P2 CEO, Neil Burns. “She has the skills, experience and attitude to help us develop a state of the art communications and engagement program for customers glo
By Michelle Tuccitto Sullo
Woodbridge-based P2 Science Inc. launched a new line of plant-based biodegradable ingredients this month that can be used in cosmetics and toiletries.
The new patented line, Citrolatum, is billed as an alternative to petrolatum, as it has a similar consistency.
P2 Science, a renewable chemistry company, has a manufacturing plant in Naugatuck and a research lab in Woodbridge, and its products are typically used in the flavor, fragrance and cosmetics markets.
The company anticipates commercial production of the new product line will start shortly at its Naugatuck facility.
Neil Burns, CEO of P2 Science, said the company developed the product line in response to requests from customers.
Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China
Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties
Shanghai Haini gains exclusive manufacturing, development and commercial rights for the licensed territory
SAINT-LOUIS, France and WEIL AM RHEIN, Germany and SHANGHAI, China, Dec. 21, 2020 (GLOBE NEWSWIRE) Shanghai Haini Pharmaceutical Co., Ltd. (Shanghai Haini), the subsidiary of Yangtze River Pharmaceutical Group (YRPG), and Allecra Therapeutics (Allecra) today announced that the companies have signed an exclusive licensing agreement under which Shanghai Haini will manufacture, develop and commercialize cefepime/enmetazobactam within Greater
December 21, 2020
December 21, 2020 | Funding updates around the life sciences including cash for a handheld mass spec device, Series D for oncolytic immunotherapy, a new company launch in allogenic CAR-NK cells, AI-powered cell classification, a 3-D sequencing platform, and more.
$170M: Israeli ‘Digital Health First’ VC Firm
OTV (formerly Olive Tree Ventures), Israel’s ‘digital health first’ venture capital firm, today announced the closing of a fund with a total value of $170M. OTV also announced their new name and the appointment of a new Head of Asia Pacific to spearhead the fund’s expansion into the region’s market. OTV is the only venture capital fund in Israel whose primary focus is digital health, specializing in supporting their portfolio companies reach maturity, refine execution, tackle regulatory hurdles and ensure a global imprint on validated products. Over the course of the past five years, OTV has prioritized investment in digital health